Literature DB >> 18487079

Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value.

Sheng-Chieh Chan1, Joseph Tung-Chieh Chang, Hung-Ming Wang, Chien-Yu Lin, Shu-Hang Ng, Kang-Hsing Fan, Shy-Chyi Chin, Chua-Ta Liao, Tzu-Chen Yen.   

Abstract

Distant failure is an important cause of death in stage M0 primary nasopharyngeal carcinoma (NPC). However, a reliable prognosticator for occurrence of distant failure was lacking. Thus, we conducted this study to investigate prospectively the role of standardized uptake value on 18F-FDG for predicting distant failure in stage M0 NPC. Patients with stage M0 primary NPC diagnosed by both conventional work-up (CWU) and 18F-FDG PET were enrolled. Survival was estimated by the Kaplan-Meier method. Cox proportional hazards models were used to identify independent prognosticators. Between January 2002 and July 2003, 65 NPC patients were investigated. Up to the date of analysis, 12 patients died and 13 patients experienced recurrences, among whom 9 had distant failures. The 5-year overall survival (OS), relapse-free survival (RFS), and distant relapse-free survival (DRFS) were 81.2%, 79.2%, 84.4%, respectively. In multivariate analysis, the following risk factors for poor prognosis were identified: T3-4 (p=0.033) for RFS; and maximal standardized uptake value (SUVmax) of the primary tumor > 12.0 (p=0.012), stage IVa-b (p=0.037), and N2-3 disease (p=0.04) for DRFS. The 5-year DRFS in stage IVa-b patients with SUVmax > 12.0 was significantly lower than that in stage I-III patients with SUVmax < or = 12 (p=0.0001). None of the patients in the latter group developed distant failure. In conclusion, a SUVmax > 12.0 of the primary tumor represents a "metabolic phenotype" for occurrence of distant failure in stage M0 NPC patients. And the combined information of SUVmax and tumor staging can guide the use of neoadjuvant/adjuvant therapy and surveillance protocols to improve distant control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487079     DOI: 10.1016/j.oraloncology.2008.03.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  21 in total

1.  [18F]-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Value as a Predictor of Adjuvant Chemotherapy Benefits in Patients With Nasopharyngeal Carcinoma.

Authors:  Te-Chun Hsieh; Ching Yun Hsieh; Tse Yen Yang; Tzu Ting Chen; Chen Yuan Lin; Ching-Chan Lin; Chung Hung Hua; Chang-Fang Chiu; Su-Peng Yeh; Yuh Pyng Sher
Journal:  Oncologist       Date:  2015-04-15

2.  ¹⁸F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study.

Authors:  Sheng-Chieh Chan; Hung-Ming Wang; Tzu-Chen Yen; Chien-Yu Lin; Shy-Chyi Chin; Chun-Ta Liao; Yau-Yau Wai; Jiun-Jie Wang; Shu-Hang Ng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-13       Impact factor: 9.236

3.  18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis.

Authors:  Peng Xie; Minghuan Li; Hanxi Zhao; Xindong Sun; Zheng Fu; Jinming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-13       Impact factor: 4.553

4.  Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.

Authors:  Peng Xie; Jin-Bo Yue; Han-Xi Zhao; Xin-Dong Sun; Li Kong; Zheng Fu; Jin-Ming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-20       Impact factor: 4.553

5.  The Prognostic Value of the Metabolic Tumor Volume in FIGO stage IA to IIB Cervical Cancer for Tumor Recurrence: Measured by F-18 FDG PET/CT.

Authors:  Bum Soo Kim; In Joo Kim; Seong-Jang Kim; Hyun-Yeol Nam; Kyoung June Pak; Keunyoung Kim; Man Soo Yun
Journal:  Nucl Med Mol Imaging       Date:  2010-11-12

6.  Prognostic value of volume-based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.

Authors:  Seung Hwan Moon; Joon Young Choi; Hwan Joo Lee; Young-Ik Son; Chung-Hwan Baek; Yong Chan Ahn; Myung-Ju Ahn; Keunchil Park; Byung-Tae Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2015-05-13       Impact factor: 3.372

7.  Adding maximum standard uptake value of primary lesion and lymph nodes in 18F-fluorodeoxyglucose PET helps predict distant metastasis in patients with nasopharyngeal carcinoma.

Authors:  Qi Shi; Zhongyi Yang; Yingjian Zhang; Chaosu Hu
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

8.  Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma--a retrospective study.

Authors:  Zhongyi Yang; Qi Shi; Yongping Zhang; Herong Pan; Zhifeng Yao; Silong Hu; Wei Shi; Beiling Zhu; Yingjian Zhang; Chaosu Hu
Journal:  Radiat Oncol       Date:  2015-01-08       Impact factor: 3.481

9.  Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.

Authors:  Ting Shen; Lin-Quan Tang; Dong-Hua Luo; Qiu-Yan Chen; Pei-Jing Li; Dong-Mei Mai; Shan-Shan Guo; Li-Ting Liu; Chao-Nan Qian; Xiang Guo; Mu-Sheng Zeng; Hao-Yuan Mo; Hai-Qiang Mai
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

10.  Pretreatment Dynamic Contrast-Enhanced MRI Improves Prediction of Early Distant Metastases in Patients With Nasopharyngeal Carcinoma.

Authors:  Shy-Chyi Chin; Chien-Yu Lin; Bing-Shen Huang; Ngan-Ming Tsang; Kang-Hsing Fan; Yi-Kang Ku; Cheng-Lung Hsu; Sheng-Chieh Chan; Shiang-Fu Huang; Cheng-He Li; Hsiao-Jung Tseng; Chun-Ta Liao; Ho-Ling Liu; Kyunghyun Sung
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.